Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
Disclosures: Tadashi Namisaki: Nothing to Disclose, Yukihisa Fujinaga: Nothing to Disclose, Shinya Sato: Nothing to Disclose, NORIHISA NISHIMURA: Nothing to Disclose, KOSUKE KAJI: Nothing to Disclose, Hitoshi Yoshiji: Nothing to Disclose 2338 ALTERED SERUM BIOMARKERS IN PRIMARY SCLEROSING CHOLANGITIS AFTER PROCTOCOLECTOMY ARE CONSISTENT WITH IMPROVED PROGNOSIS AND REDUCED GUT MICROBIAL IMPACT Sara Kristina Viberg Tjnnfjord 1 Trine Folseraas 1 Hlmfrur Helgadttir 1 Arild Nesbakken 2 Ragnhild Lothe 3 Per Magne Ueland 4 Adrian McCann 4 William Rosenberg 5 Tom Karlsen 1 Mette Vesterhus 1 Johannes Hov 1 Peder Rusten Braadland 1 , 1 Norwegian PSC Research Center, 2 Institute of Cancer Research, 3 Institute for Cancer Research, 4 BEVITAL AS, 5 University College London Medical School Background: Proctocolectomy has recently been associated with improved outcomes in people with primary sclerosing cholangitis (PSC)
Disgusting that shes trying to push weight-loss drugs, wrote one commenter
The incretin hormone receptors (GIPR and GLP-1R) are widely distributed beyond the pancreas, principally in the brain, cardiovascular and immune systems, gut and kidney, consistent with a broad array of extrapancreatic incretin actions
The accompanying inverted pyramid image places beef near the top, positioning it as a prominent protein source
Some people regain weight after stopping GLP-1 medications
